These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30309853)

  • 1. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.
    Casagrande N; Borghese C; Visser L; Mongiat M; Colombatti A; Aldinucci D
    Haematologica; 2019 Mar; 104(3):564-575. PubMed ID: 30309853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma.
    Casagrande N; Borghese C; Favero A; Vicenzetto C; Aldinucci D
    Cancer Lett; 2021 Mar; 500():182-193. PubMed ID: 33326840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions.
    Aldinucci D; Lorenzon D; Cattaruzza L; Pinto A; Gloghini A; Carbone A; Colombatti A
    Int J Cancer; 2008 Feb; 122(4):769-76. PubMed ID: 17935139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCR5-Mediated Signaling Is Involved in Invasion of Glioblastoma Cells in Its Microenvironment.
    Novak M; Koprivnikar Krajnc M; Hrastar B; Breznik B; Majc B; Mlinar M; Rotter A; Porčnik A; Mlakar J; Stare K; Pestell RG; Lah Turnšek T
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy.
    Nie Y; Huang H; Guo M; Chen J; Wu W; Li W; Xu X; Lin X; Fu W; Yao Y; Zheng F; Luo ML; Saw PE; Yao H; Song E; Hu H
    Clin Cancer Res; 2019 Jul; 25(13):3873-3886. PubMed ID: 30890553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis.
    Pervaiz A; Zepp M; Georges R; Bergmann F; Mahmood S; Faiza S; Berger MR; Adwan H
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):73-91. PubMed ID: 32902795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability.
    Casagrande N; Borghese C; Aldinucci D
    Haematologica; 2022 Jan; 107(1):287-291. PubMed ID: 34498447
    [No Abstract]   [Full Text] [Related]  

  • 8. CCR5 antagonist treatment inhibits vascular injury by regulating NADPH oxidase 1.
    Singh S; Bruder-Nascimento A; Belin de Chantemele EJ; Bruder-Nascimento T
    Biochem Pharmacol; 2022 Jan; 195():114859. PubMed ID: 34843718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment.
    Wang SW; Liu SC; Sun HL; Huang TY; Chan CH; Yang CY; Yeh HI; Huang YL; Chou WY; Lin YM; Tang CH
    Carcinogenesis; 2015 Jan; 36(1):104-14. PubMed ID: 25330803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Jin K; Pandey NB; Popel AS
    Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CR5/CCL5 axis is linked to a poor outcome, and inhibition reduces metastasis in oral squamous cell carcinoma.
    González-Arriagada WA; Coletta RD; Lozano-Burgos C; García C; Maripillán J; Alcayaga-Miranda F; Godínez-Pacheco B; Oyarce-Pezoa S; Martínez-Flores R; García IE
    J Cancer Res Clin Oncol; 2023 Dec; 149(19):17335-17346. PubMed ID: 37831273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5 as a treatment target in pulmonary arterial hypertension.
    Amsellem V; Lipskaia L; Abid S; Poupel L; Houssaini A; Quarck R; Marcos E; Mouraret N; Parpaleix A; Bobe R; Gary-Bobo G; Saker M; Dubois-Randé JL; Gladwin MT; Norris KA; Delcroix M; Combadière C; Adnot S
    Circulation; 2014 Sep; 130(11):880-891. PubMed ID: 24993099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme.
    Kranjc MK; Novak M; Pestell RG; Lah TT
    Radiol Oncol; 2019 Nov; 53(4):397-406. PubMed ID: 31747383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It.
    Aldinucci D; Borghese C; Casagrande N
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression.
    D'Antoni ML; Mitchell BI; McCurdy S; Byron MM; Ogata-Arakaki D; Chow D; Mehta NN; Boisvert WA; Lefebvre E; Shikuma CM; Ndhlovu LC; Baumer Y
    J Leukoc Biol; 2018 Dec; 104(6):1241-1252. PubMed ID: 30088682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokine CCR5 and cocaine interactions in the brain: Cocaine enhances mesolimbic CCR5 mRNA levels and produces place preference and locomotor activation that are reduced by a CCR5 antagonist.
    Nayak SU; Cicalese S; Tallarida C; Oliver CF; Rawls SM
    Brain Behav Immun; 2020 Jan; 83():288-292. PubMed ID: 31557508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer.
    Sax MJ; Gasch C; Athota VR; Freeman R; Rasighaemi P; Westcott DE; Day CJ; Nikolic I; Elsworth B; Wei M; Rogers K; Swarbrick A; Mittal V; Pouliot N; Mellick AS
    Oncotarget; 2016 Dec; 7(51):85437-85449. PubMed ID: 27863423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward.
    Gonek M; McLane VD; Stevens DL; Lippold K; Akbarali HI; Knapp PE; Dewey WL; Hauser KF; Paris JJ
    Brain Behav Immun; 2018 Mar; 69():124-138. PubMed ID: 29146238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer.
    Pervaiz A; Zepp M; Mahmood S; Ali DM; Berger MR; Adwan H
    Cell Oncol (Dordr); 2019 Feb; 42(1):93-106. PubMed ID: 30456574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction.
    Huang H; Zepp M; Georges RB; Jarahian M; Kazemi M; Eyol E; Berger MR
    Cancer Lett; 2020 Apr; 474():82-93. PubMed ID: 31954769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.